Last $2.94 USD
Change Today +0.04 / 1.38%
Volume 391.4K
THLD On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

threshold pharmaceuticals (THLD) Snapshot

Open
$2.90
Previous Close
$2.90
Day High
$3.00
Day Low
$2.90
52 Week High
01/22/14 - $5.93
52 Week Low
11/7/14 - $2.58
Market Cap
184.5M
Average Volume 10 Days
513.4K
EPS TTM
$-0.39
Shares Outstanding
62.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for THRESHOLD PHARMACEUTICALS (THLD)

threshold pharmaceuticals (THLD) Related Businessweek News

No Related Businessweek News Found

threshold pharmaceuticals (THLD) Details

Threshold Pharmaceuticals, Inc., a biotechnology company, discovers and develops therapeutic agents that target tumor cells for the treatment of patients living with cancer in the United States. Its lead investigational small molecule, TH-302, is being evaluated in two pivotal Phase III clinical trials for the treatment of soft tissue sarcoma indication and pancreatic cancer; and various earlier-stage clinical trials for therapeutic areas, including advanced leukemias, multiple myeloma, advanced renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors. Threshold Pharmaceuticals, Inc. has a license and co-development agreement with Merck KGaA to co-develop and commercialize TH-302; and license agreement with Eleison Pharmaceuticals, Inc. for the development and commercialization of glufosfamide for the treatment of cancer in humans and animals. The company was founded in 2001 and is headquartered in South San Francisco, California.

61 Employees
Last Reported Date: 11/3/14
Founded in 2001

threshold pharmaceuticals (THLD) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $575.0K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $263.0K
Senior Vice President of Clinical Operations ...
Total Annual Compensation: $418.4K
Senior Vice President of Discovery Research
Total Annual Compensation: $398.4K
Chief Medical Officer
Total Annual Compensation: $361.0K
Compensation as of Fiscal Year 2013.

threshold pharmaceuticals (THLD) Key Developments

Threshold Pharmaceuticals, Inc. Announces Encouraging Interim Data from Phase I/II Glioblastoma Trial

Threshold Pharmaceuticals Inc. has announced encouraging interim data from a US investigator-sponsored Phase I/II clinical trial of its anticancer drug, TH-302, in combination with bevacizumab for the treatment of glioblastoma, or GBM. All patients in the study had previously progressed on single-agent bevacizumab, the only FDA-approved therapy for GBM patients with progressive disease following prior therapy. As reported by the investigator, in a total of 22 evaluable patients, best responses included one complete response and three partial responses for a response rate of 18%, and ten stable disease assessments for a clinical benefit rate of 64%; eight patients had progressive disease. Median progression-free survival was 2.8 months, and median overall survival was 4.6 months. In addition, the FDA, through its Office of Orphan Product Development, recently awarded Dr. Brenner a grant for a Phase II clinical trial of TH-302 for the treatment of GBM. As reported at SNO, a total of 23 patients in the Phase I/II study were treated with bevacizumab 10 mg/kg every two weeks and TH-302 dose escalated 240-670 mg/m2 every two weeks (four-week cycle) until disease progression. Patients had received a median of three prior systemic anticancer regimens including both chemoradiation and bevacizumab. No grade 4 adverse events (AEs) were observed. Three grade 3 AEs in three patients were observed: skin ulceration at 340 mg/m2, thrombocytopenia at 670 mg/m2, and oral mucositis at 670 mg/m2. Primary TH-302-related toxicities were mucosal, but were not dose limiting: rectal mucositis in one of four (1/4) patients at 480 mg/m2 and all patients (13/13) at 670 mg/m2 (all grade 1 or 2). Oral mucositis was less frequent. Best tumor responses in 22 patients evaluable by RANO criteria included one complete response and three partial responses for a response rate of 18%, and ten stable disease assessments for a clinical benefit rate of 64%; eight patients had progressive disease. Median progression-free survival was 2.8 months (95% confidential interval (CI): 1.9 to 3.9 months) and 4-month progression-free survival was 22% (95% CI: 3.2% to 41%). Median overall survival was 4.6 months (95% CI: 3.4 to 6.2 months). The planned investigator-sponsored Phase II trial, which is designed to assess safety and efficacy of 670 mg/m2 TH-302 in combination with bevacizumab for the treatment of recurrent GBM following prior bevacizumab failure, is expected to enroll up to 33 patients. PET imaging will also be conducted in an effort to predict which patients may benefit from TH-302 combination therapy. Dana Farber Cancer Institute and The University of Texas at Austin will participate in the trial. Threshold and Merck KGaA, Darmstadt, Germany, will provide TH-302 for the trial.

Threshold Pharmaceuticals Receives U.S. Food and Drug Administration Fast Track Designation for TH-302

Threshold Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for TH-302, an investigational anticancer drug, for the treatment of previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcoma (STS). The FDA established the Fast Track designation process to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. An important feature of Fast Track is that the FDA may consider a rolling review of completed sections of the New Drug Application (NDA) before the complete application is submitted. Threshold is conducting this international, randomized pivotal Phase 3 clinical trial in partnership with the Sarcoma Alliance for Research through Collaboration (SARC) and under a Special Protocol Assessment (SPA) agreement with the U.S. FDA. The trial is designed to investigate the efficacy and safety of TH-302 in combination with doxorubicin, compared with doxorubicin alone, in previously untreated patients with metastatic or locally advanced unresectable STS. The primary endpoint of the trial is overall survival. Secondary endpoints include progression-free survival, overall response rate, pharmacokinetics and safety. Patients were randomized to either doxorubicin alone or to receive TH-302 300 mg/m(2) administered intravenously on Days 1 and 8 with doxorubicin 75 mg/m(2) on Day 1 of each 21-day cycle. After six cycles, patients with stable and/or responding disease could receive maintenance monotherapy with TH-302 according to the same dosing schedule, 300 mg/m(2) Days 1 and 8 of each 21-day cycle. The trial enrolled a total of 640 patients across 81 study sites in Europe, Israel, North America and the Russian Federation.

Threshold Pharmaceuticals Inc. Presents at Brean Capital Life Sciences Summit, Nov-24-2014

Threshold Pharmaceuticals Inc. Presents at Brean Capital Life Sciences Summit, Nov-24-2014 . Venue: Convene (Formerly Sentry Centers), 730 3rd Avenue, New York, New York, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
THLD:US $2.94 USD +0.04

THLD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for THLD.
View Industry Companies
 

Industry Analysis

THLD

Industry Average

Valuation THLD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THRESHOLD PHARMACEUTICALS, please visit www.thresholdpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.